Quantcast
Last updated on April 18, 2014 at 7:29 EDT

Latest GenomeDx Biosciences Stories

2014-04-11 08:24:36

SAN DIEGO, April 11, 2014 /PRNewswire/ -- GenomeDx Biosciences announced today that two study abstracts for the company's genomic tests for prostate and bladder cancers have been selected as "Best Posters in a Poster Session" by conference organizers at the 29(th) Annual European Association of Urology Congress. The first poster presentation demonstrates the clinical validation of the Decipher® prostate cancer classifier for predicting treatment failure in men treated with...

2014-03-04 08:31:51

SAN DIEGO, March 4, 2014 /PRNewswire/ -- GenomeDx Biosciences announced that it will present today at the 34(th) Annual Cowen and Company Healthcare Conference at 4:30 p.m. ET in Boston, Massachusetts. Doug Dolginow, M.D., CEO of GenomeDx, will provide a progress update on the commercialization of its Decipher® test and an overview of the Company's product pipeline in urology. About Decipher® The Decipher Prostate Cancer Classifier is a genomic test that directly measures the...

2014-02-03 08:27:25

SAN DIEGO, Feb. 3, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement to provide its Decipher(®) prostate cancer test to FEDMED Payors. FEDMED is a national provider network that covers over 40 million lives. The Decipher( )prostate cancer classifier directly measures a patient's biological risk of developing metastatic prostate cancer. GenomeDx, which discovered and developed the Decipher test, will provide laboratory services...

2014-01-30 08:31:31

Multiple Studies of Decipher Prostate Cancer Classifier Presented at 2014 ASCO Genitourinary Symposium SAN DIEGO, Jan. 30, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced new data demonstrating that its Decipher® Prostate Cancer Classifier, a genomic test capable of predicting the probability of developing metastatic prostate cancer, outperformed existing clinical risk factors for predicting biochemical failure and distant metastasis following radiation therapy. In addition,...

2013-11-20 08:28:30

SAN DIEGO, Nov. 20, 2013 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into contractual agreements for diagnostic laboratory testing as a participating provider with three separate private PPO Networks, bringing the Decipher® test to their networks of over 62.6 million covered lives. The three PPO networks are Stratose Inc., Three Rivers Provider Network and Fortified Provider Network. "We are focusing on providing access to patients who can benefit from...

2013-06-25 08:29:06

Decipher genomic test independently forecasts risk of metastatic disease better than PSA, Gleason Score, and other commonly used risk assessment tools as determined by clinical outcomes SAN DIEGO, June 25, 2013 /PRNewswire/ -- GenomeDx Biosciences today announced the publication of data demonstrating its Decipher(TM) test outperformed existing risk assessment tools for predicting metastatic prostate cancer in patients following prostate surgery. Decipher more accurately...

2013-05-29 23:21:50

New iPad App Developed for GenomeDx Biosciences Enables Urologists to Share Interactive 3D Models with Patients to Enhance Patient Understanding and Allow More In-depth Consultations Vancouver, BC (PRWEB) May 29, 2013 Conquer Mobile, a fast growing developer of secure, custom mobile apps, announced that they have delivered an innovative mHealth app for GenomeDx Biosciences. The iPad app, UroSketch 3D, provides an interactive 3D model of the male pelvis and is now available for download on...

2013-05-08 16:26:46

Two Johns Hopkins University School of Medicine studies presented at the 2013 AUA Annual Meeting demonstrate Decipher's ability to outperform existing tools for predicting metastasis and disease progression SAN DIEGO, May 8, 2013 /PRNewswire/ -- GenomeDx Biosciences today announced that data presented by Johns Hopkins University School of Medicine researchers at the 2013 Annual Meeting for the American Urological Association demonstrated that Decipher(TM), a transformative genomic...

2013-05-03 08:25:34

New app gives urologists the ability to share three-dimensional models of vital organs with patients for more complete, in-depth consultations SAN DIEGO and VANCOUVER, British Columbia, May 3, 2013 /PRNewswire/ -- GenomeDx Biosciences today announced the launch of UroSketch 3D(TM), an application available in Apple's App Store and designed specifically for the iPad. The app, which provides a three-dimensional model of the prostate, bladder and surrounding organs for use by physicians...

2013-04-29 08:27:42

Additional validation data of Decipher(TM) prostate cancer test to be presented at AUA 2013 SAN DIEGO, April 29, 2013 /PRNewswire/ -- GenomeDx Biosciences announced today that it has expanded an existing research agreement with the Mayo Clinic. The expanded agreement includes exclusive license to certain Mayo developed intellectual property along with exclusivity covering co-developed intellectual property. The agreement also includes continued access to the clinical data...